Endeavor

New Immunotherapy Combination Shows Promise in Advanced Lung Cancer

Adding pembrolizumab to TIL therapy shrunk tumors in almost half of trial patients

Moffitt Experts Share Discoveries Driving Innovation in Cancer Immunotherapy

The Society for Immunotherapy of Cancer brings together industry leaders to highlight new research and clinical applications in immunotherapy

Moffitt Hosts Inaugural Cell Coast Conference to Spotlight Breakthroughs in Cellular Immunotherapy

Experts discuss the latest advances in CAR T, TIL and TCR therapies

What Is Immunotherapy?

Harnessing the immune system to attack cancer gives patients new treatment options

Next Generation of TIL Therapy Being Developed for Head and Neck Cancers

Standard of care fails 80% of patients with advanced squamous cell carcinoma

Moffitt Treats its First Commercial TIL Therapy Patient Since FDA Approval

The one-time T-cell therapy infusion was approved in February

The Long Journey in Search of a Cure

With one TIL therapy approved by the FDA, doctors push to optimize the treatment. Michelle Shannon is living for the next breakthrough.

Expanding the Reach of TIL Therapy

Based on the success in treating melanoma, doctors see promise in using the immunotherapy to treat sarcoma and other cancers

Past Gift Sparks Future Breakthroughs and FDA Approval

Donation made 17 years ago changed the future of cancer research at Moffitt